Connect Biopharma Holdings Ltd (CNTB)
| Market Cap | 58.81M-48.7% |
| Revenue (ttm) | 2.95M |
| Net Income | -68.99M |
| EPS | -1.19 |
| Shares Out | 62.97M |
| PE Ratio | n/a |
| Forward PE | -1.34 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 198,129 |
| Open | 0.92 |
| Previous Close | 0.94 |
| Day's Range | 0.92 - 0.96 |
| 52-Week Range | 0.85 - 3.82 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 5.88(+529.08%) |
| Earnings Date | n/a |
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About CNTB
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$CNTB stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in CNTB holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CNTB's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CNTB Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New CNTB patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CNTB from public contracts
Source: USAspending.gov
CNTB Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CNTB’s recent data — informational, not investment advice